Olanap ODT 5 mg (Dispersible Tablet)
Medicine Details
| Category | Details |
|---|---|
| Generic | Olanzapine |
| Company | Incepta pharmaceuticals ltd |
| Also available as |
Indications
Acute and maintenance treatment of schizophrenia, treatment of acute manic or mixed episodes in bipolar disorder
Pharmacology
Affinities for serotonin 5HT2A/2C, 5HT3, 5HT6; dopamine D1, D2, D3, D4, D5; cholinergic muscarinic receptors M1-M5; α1 adrenergic; and histamine H1 receptors; mechanism of action is unknown; well absorbed after oral administration
Dosage
Initial dose 5-10 mg once daily for schizophrenia and bipolar disorder; dosage may be adjusted within the range of 5-20 mg daily; maximum dose 20 mg daily
Administration
Can be given without regard to meals; gradual tapering of the dose should be considered while discontinuing
Interaction
May antagonize the effects of levodopa and dopamine agonists; clearance may be affected by drugs inducing or inhibiting CYP1A2 or glucoronyl transferase enzymes; caution with centrally acting drugs and alcohol
Contraindications
Known hypersensitivity to any ingredient; known risk for narrow-angle glaucoma
Side Effects
- Somnolence
- Weight gain
- Increased appetite
- Elevated glucose levels
- Elevated triglyceride levels
- Dizziness
- Akathisia
- Parkinson's disease
- Dyskinesia
- Orthostatic hypotension
- Anticholinergic effects
- Constipation
- Dry mouth
- Asthenia
- Edema
- Photosensitivity reaction
Pregnancy & Lactation
Use in pregnancy only if potential benefits justify potential risk to fetus; advise patients to notify physician if pregnant or intend to become pregnant; should not breastfeed while taking
Precautions & Warnings
- Use cautiously in patients with history of seizures
- Use cautiously in patients with low leukocyte and/or neutrophil counts
- Use cautiously in patients with impaired hepatic function
- Caution about operating hazardous machinery
- Use cautiously in the elderly
- Caution for patients using hepatotoxic medicines
- Caution for patients using centrally acting drugs
- Caution for patients using medicines known to increase QT interval
Use in Special Populations
- Children: Not studied in subjects under 18 years of age
- Elderly patients: Starting dose 5 mg/day
- Patients with hepatic, renal impairment: Starting dose 5 mg/day
Therapeutic Class
Atypical neuroleptic drugs
Storage Conditions
Keep below 30°C temperature, away from light & moisture; keep out of the reach of children